Evaluation of a PAK1-selective PROTAC, alone and with Hippo inhibitors, as a targeted therapy in NF2

syn27261816

Created By review-service

grantDOI: https://doi.org/10.48105/pc.gr.151488
studyName: Evaluation of a PAK1-selective PROTAC, alone and with Hippo inhibitors, as a targeted therapy in NF2
dataStatus: Data Pending
initiative: Drug Discovery Initiative Registered Reports
studyLeads: Jonathan Chernoff
studyStatus: Active
diseaseFocus: Neurofibromatosis type 2
institutions: Fox Chase Cancer Center
fundingAgency: CTF
manifestation: Schwannoma
relatedStudies: syn27261829 syn22268652 syn35632706 syn27761862
studyFileviewId: syn27261823
syn27261817
syn27261819
syn27261823
syn27261820

Your web browser must have JavaScript enabled in order for this application to display correctly.
If you are an automated web crawler from a search engine, follow this AJAX application crawl link

Evaluation of a PAK1-selective PROTAC, alone and with Hippo inhibitors, as a targeted therapy in NF2

syn27261816

Drop files to upload

Evaluation of a PAK1-selective PROTAC, alone and with Hippo inhibitors, as a targeted therapy in NF2 page is loading…